3M Company (MMM) FY2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed February 3, 2026, FY ended December 31, 2025) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Unqualified opinion (1 critical audit matter: PFAS-related legal proceedings)

One-line verdict: 3M is a multi-year litigation workout in the shape of a manufacturing company. Net sales rose just 1.5% to $24.95B, GAAP EPS fell 17% to $6.00, and four screening checks fail: CFFO below net income for three consecutive years (C1), FCF below 50% of net income for two years (C2), cash of $5.93B covering only 47% of $12.60B debt (C4), and goodwill+intangibles of $7.5B at 160% of equity (D1). Plus one watch item (A2 AR growth 10.6% vs revenue 1.5%). The business is going through its final PFAS exit — "3M completed its exit of PFAS manufacturing at the end of 2025" — while working through a $12.5B PWS Settlement and $6.0B CAE Settlement that it has already paid $8.2B against. PwC's critical audit matter centers on these "other environmental liabilities" of $7.7B. The April 2024 Solventum separation removed the Health Care business and reduced equity. GAAP operating margin fell 100bps to 18.6% but adjusted margin (excluding PFAS-related litigation and transformation costs) rose 200bps to 23.4%. The aggressive $3.3B buyback in 2025 plus dividend continues to shrink equity while litigation liabilities remain on the balance sheet.

A Company Defined by Its Legal Liabilities

From the MD&A overview: "3M is a diversified global manufacturer, technology innovator and marketer of a wide variety of products and services... 3M manages its continuing operations in three operating business segments: Safety and Industrial; Transportation and Electronics; and Consumer."

The MD&A opens with the defining corporate action: "on April 1, 2024, 3M completed the separation of its Health Care business (the Separation) through a pro rata distribution of 80.1% of the outstanding shares of Solventum Corporation (Solventum) to 3M stockholders. As a result, Solventum became an independent public company, 3M no longer consolidated Solventum into 3M's financial results and the historical net income of Solventum, and applicable assets and liabilities included in the Separation were reported in 3M's consolidated financial statements as discontinued operations."

And the second defining action: "3M completed its exit of PFAS manufacturing at the end of 2025 as discussed in Part I, Item 1A, Risk Factors of this document. Decisions or circumstances associated with the extent and type of remaining activity at particular locations and impacts on assets and potential obligations, among other factors, could result in additional expenses."

Two major corporate restructurings in consecutive years — plus ongoing PFAS litigation — mean FY2025 financials are not comparable to pre-2023 3M in any meaningful way.

Financial Performance: Organic Growth is Weak

From the MD&A financial highlights table:

Per the MD&A: "Net sales change was driven by strength in safety and general industrial and supported by commercial excellence and new product introductions. These were partially offset by known softness in auto aftermarket, roofing granules, commercial vehicles, and consumer, and the YoY impact of the manufactured PFAS products special item."

Organic sales growth of 0.9% is modest. The adjusted number (excluding the PFAS manufacturing exit drag) at 2.1% is better but still below inflation. This is not a growing business.

The GAAP vs non-GAAP gap is large — $2.06 per share in FY2025 special items. Breakdown:

Net costs for significant litigation alone was $1.06B in FY2025. This is the PWS Settlement, CAE Settlement, respirator mask/asbestos, Aearo, and PFAS-related other environmental matters. The MD&A separately notes: "the Company expects to pay up to $12.5 billion in the aggregate from 2023 through 2036 pursuant to the terms of the PWS Settlement and expects to pay up to $6.0 billion in the aggregate from 2023 to 2029 pursuant to the terms of the CAE Settlement. Through December 31, 2025, 3M has paid $8.2 billion in aggregate relating to these settlements."

Segment operating income (GAAP):

Cost of sales as % of sales rose from 58.8% to 60.1% (+130bps). The MD&A attributes this to: "foreign currency impacts; tariffs; the exit of manufactured PFAS products; and net costs for significant litigation for updates to site remediation obligations." Tariffs appear explicitly in the cost-of-sales discussion — 3M's global footprint means tariff cost exposure is broad.

SG&A fell from 17.2% to 16.0% of sales (-120bps) due to "lower YoY restructuring charges, ongoing cost discipline and productivity, and benefits from insurance recoveries in 2025." Insurance recoveries on historic litigation are a recurring theme.

Effective tax rate rose from 16.7% to 23.8%. The MD&A explains: "The primary factors that increased the Company's 2025 effective tax rate when compared to 2024 were the tax impact of 3M's retained ownership interest in Solventum and net costs of significant litigation."

Cash Flow: Three Years of CFFO Below Net Income

Per the MD&A: "In 2025, cash flows provided by operating activities increased by $0.5 billion compared to the same period last year, primarily driven by lower payments associated with PFAS-related environmental liabilities and the CAE legal settlement."

C1 fails: CFFO below net income for three consecutive years (or more, given the FY2023 loss). The mechanical cause is the litigation-settlement cash outflows — those are cash payments that reduce CFFO but were already accrued in prior periods as non-cash charges.

C2 fails: FCF below 50% of net income. FCF/NI ratios of 0.43 (FY25) and 0.15 (FY24) are both below the 0.5 threshold.

The MD&A notes CapEx is rising: "The Company expects 2026 capital spending to be approximately $1.1 billion as 3M continues to invest in growth, productivity and sustainability." Up from $0.9B in FY2025.

The real CFFO story is that 3M's underlying operating cash generation (before litigation cash-outs) is in the $4-5B range, consistent with the $5-6B range pre-Solventum separation. The reported CFFO of $2.31B in FY2025 already reflects several billion of litigation payments. As those settlement obligations continue through 2036 (PWS) and 2029 (CAE), CFFO will remain depressed relative to net income for the foreseeable future.

Balance Sheet: Litigation Liabilities and Stock Buybacks

From the CAM disclosure: "As of December 31, 2025, the Company had recorded liabilities of $7.7 billion for other environmental liabilities, the majority of which relate to PFAS-related legal proceedings."

Equity is thin: Per D1 showing 160% goodwill/equity, equity is approximately $4.7B against goodwill+intangibles of $7.5B. This is the result of:

Per the MD&A on buybacks: "In February 2025, 3M's Board of Directors replaced the Company's 2018 repurchase program with a new repurchase program. This new program authorizes the repurchase of up to $7.5 billion of 3M's outstanding common stock, with no pre-established end date... In 2025, the Company purchased $3.3 billion of its own stock, compared to $1.8 billion of stock purchases in 2024. As of December 31, 2025, approximately $4.6 billion remained available under the authorization."

Dividend policy: "3M has paid dividend continuously since 1916. Cash dividends declared and paid totaled $0.73 per share for each quarter of 2025." And: "In February 2026, 3M's Board of Directors declared a first-quarter 2026 dividend of $0.78 per share, an increase of 7 percent."

Debt profile: "Debt cash flow activity includes $1.8 billion aggregate principal amount of debt maturities partially offset by proceeds from issuance of $1.1 billion in aggregate principal amount of debt in 2025." Net debt reduction of $700M in 2025.

C4 fails: Cash $5.93B / Total debt $12.6B = 47%. Just below the 50% threshold — MMM is right at the borderline for this check, and the Altman Z-Score of 5.55 confirms the overall balance sheet is safe from a distress standpoint.

D1 fails: The $7.5B goodwill+intangibles against ~$4.7B equity is a real concern — any meaningful impairment of the industrial segments' goodwill would push equity materially lower.

The 18-Point Screening

Revenue Quality

A2 watch: The 9-point gap between AR growth (+10.6%) and revenue growth (+1.5%) warrants attention. The DSO change of +4 days (from 48 to 52) confirms this: receivables are taking longer to collect. The absolute DSO is not alarming, but the trend is negative. Possible explanations include: (1) the PFAS manufacturing exit created timing disruptions, (2) tariffs are causing customers to push back on price increases, slowing collections, or (3) the Consumer segment softness is leading to slow-paying distributors.

Expense Quality

Cash Flow Quality

C1 and C2 together are the cash-flow quality signal. Note that both are caused by the same underlying dynamic — litigation cash payments exceeding litigation expense accruals — rather than operating deterioration. The MD&A is explicit that "lower payments associated with PFAS-related environmental liabilities" drove the FY2025 CFFO improvement, meaning the drag is still meaningful in absolute terms.

Balance Sheet

Acquisition Risk

Manipulation Score

M-Score components: DSRI 1.090, GMI 1.033, AQI 0.907, SGI 1.015, DEPI 1.001, SGAI 0.933, TATA 0.025, LVGI 0.969. DSRI of 1.09 reflects the AR-to-revenue mismatch captured in A2. TATA positive at 0.025 reflects the CFFO/NI gap captured in C1. These two components are individually small but jointly push the M-Score close to the -2.22 grey-zone threshold. Without the litigation cash-outs distorting CFFO, the M-Score would be meaningfully cleaner.

Key Risks from the 10-K

1. Critical Audit Matter: PFAS-Related Legal Proceedings

PwC's CAM is directly about the PFAS liability: "As of December 31, 2025, the Company had recorded liabilities of $7.7 billion for other environmental liabilities, the majority of which relate to PFAS-related legal proceedings. These accruals represent management's estimate of probable loss for PFAS-related matters and litigation."

PwC's procedures: "(ii) evaluating existing accruals, including the determination of the net present value of the future settlement payments, by obtaining and inspecting executed settlement agreements; (iii) evaluating the status of significant known and potential litigation and settlement activity based on inquiry of internal legal counsel, as well as external legal counsel, when deemed necessary; (iv) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel; (v) evaluating the reasonableness of management's assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable."

PwC has served as 3M's auditor for 120+ years (tenure since 1907 based on historical disclosures). The 7.7B accrual does NOT represent the full potential liability — the PWS Settlement alone is $12.5B through 2036 and the CAE Settlement is $6.0B through 2029. Only the probable-and-estimable portions are accrued.

2. PFAS Litigation Overhang

The risk factors: "governments in the United States and internationally have increasingly been regulating a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as PFAS, including some produced by the Company prior to the end of 2025... 3M announced in December 2022 it would take two further actions with respect to PFAS (2022 PFAS Announcement): exiting all PFAS manufacturing by the end of 2025, and working to discontinue the use of PFAS across its product portfolio by the end of 2025. 3M completed its exit of PFAS manufacturing at the end of 2025."

3M has paid $8.2B of the potential $18.5B in total PWS+CAE settlements so far. That means another $10.3B of cash payments are committed through 2036.

3. Tariff Exposure

The MD&A: 3M "derived approximately 56 percent of its revenues from outside the United States." And: "Cost of sales... increases in 2025 were primarily due to foreign currency impacts; tariffs; the exit of manufactured PFAS products..."

4. Solventum Retained Interest

3M retained a 19.9% stake in Solventum at separation. Per the MD&A: "Solventum ownership - change in value: decreased by approximately $1.2 billion in 2025 and increased by approximately $1.6 billion in 2024." These are mark-to-market changes that flow through other income. A $1.6B positive swing in 2024 followed by a $1.2B negative swing in 2025 = $2.8B of volatility over two years from a single non-operating asset.

5. Tariff and Supply Chain

The risk factors: "Further escalation of specific trade tensions, including those between the U.S. and China, or more broadly in global trade conflict, could have a material adverse effect on the Company's business and operations around the world." Cost of sales was up 130bps, partly attributed to tariffs.

6. Respirator Mask / Asbestos / Combat Arms Earplugs Legacy Claims

In addition to PFAS, 3M carries litigation exposure from legacy Aearo businesses (Combat Arms Earplugs) and respirator masks. These are accrued separately within the $7.7B environmental liabilities disclosed.

7. Transformation Program Costs

The "Transformation costs" special item: "These represent net costs associated with 3M's transformation program, intended as a structural redesign of longer-term manufacturing, distribution, and business process services and locations." $69M in 2025 — smaller than prior years, suggesting the program is winding down.

Summary

Grade: F. Four checks fail (C1, C2, C4, D1) plus one watch (A2) — but the story is overwhelmingly about historic liabilities, not current operating quality.

3M's adjusted operating margin of 23.4% (up 200bps) and organic sales growth of 2.1% (ex-PFAS) represent an improving operating business after the Solventum spin. The GAAP results are drowned out by $1.06B of litigation costs, $292M of PFAS exit costs, and $162M of divestiture losses — special items totaling $1.52B pre-tax.

The F grade is mechanical: three years of CFFO below net income (because of the $8.2B of already-paid PWS/CAE settlements), FCF below 50% of NI for two years, cash at only 47% of debt, and goodwill at 160% of equity. None of these individual checks capture a manipulation concern; collectively they reflect a balance sheet that has been emptied by simultaneous actions: distributing Solventum, paying down litigation claims, buying back stock ($3.3B in FY2025), and paying dividends ($1.6B in FY2025).

The real investment question is whether the PFAS and other legacy liabilities are sized correctly. PwC's CAM language is careful: the $7.7B accrual represents "probable" and "estimable" losses. The cap on PWS ($12.5B) and CAE ($6.0B) settlements alone is $18.5B, of which $8.2B has been paid — leaving $10.3B in scheduled payments through 2036. Those are contractually committed amounts. Additional PFAS-related claims beyond the settlements could increase the accrual.

The $4.6B remaining buyback authorization combined with the 7% dividend increase suggests management is still actively returning capital while the business is under litigation pressure. If litigation cash outflows continue at $1-2B per year, the balance sheet will remain tight. The thesis for MMM improvement is: PFAS exit is complete, litigation cash-outs peak soon, adjusted operating margin expansion continues, and the buyback gradually shrinks share count. The risk is any unexpected litigation expansion that pushes the environmental accrual higher.

**Disclaimer**: This report is based on 3M Company's FY2025 10-K filed with SEC EDGAR. This is NOT investment advice.

Data: SEC EDGAR 10-K + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter — PFAS-related legal proceedings)

Fiscal year ended: December 31, 2025